Poster Presentations
Apr 15, 2010
Poster Board Number
Category 13. LATE-BREAKERS:
| PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NITAZOXANIDE PLUS PEGINTERFERON AND RIBAVIRIN IN HCV GENOTYPE 1 NAïVE PATIENTS: WEEK 12 SUSTAINED VIROLOGIC RESPONSE RATE B.R. Bacon1*, M.L. Shiffman2, J.K. Lim3, A. Berman4, V.K. Rustgi5, E.B. Keeffe6,7 1Division of Gastroenterology and Hepatology, St Louis University Medical Center, St Louis, MO, 2Liver Institute of Virginia, Bon Secours Health System, Newport News, VA, 3Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, 4Florida Center for Gastroenterology, Largo, FL, 5Georgetown University Medical Center, Washington, DC, 6The Romark Institute for Medical Research, Romark Laboratories, L.C., Sausalito, 7Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA. *baconbr@slu.edu | 2001 |
| SLC28A2 65C>T PREDICT SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH HEPATITIS C TREATED WITH INTERFERON AND RIBAVIRIN, CONSIDERING ALL HCV GENOTYPE AND GENOTYPE 1/4 A. D'Avolio1, A. Ciancio2*, M. Siccardi1, L. Baietto1, M. Simiele1, S. Patanella1, D. Aguilar Marucco1, G. Cariti1, A. Calcagno1, M. Sciandra1, A. Smedile2, F.G. De Rosa1, S. Bonora1, M. Rizzetto2, G. Di Perri1 1Department of Infectious Diseases, 2Department of GastroHepatology, University of Turin, Turin, Italy. *alessiaciancio@libero.it | 2002 |
| ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND TOLERABILITY OF AZD7295, A NOVEL NS5A INHIBITOR, IN A PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY IN HCV GENOTYPE 1 AND 3 PATIENTS E. Gane1*, G.R. Foster2, J. Cianciara3, C. Stedman4, S. Ryder5, M. Buti6, E. Clark7, D. Tait7 1Auckland City Hospital, Auckland, New Zealand, 2Queen Mary University of London, The Royal London Hospital, London, UK, 3Regional Hospital of Infectious Diseases, Warsaw, Poland, 4Christchurch Clinical Studies, Christchurch, New Zealand, 5Nottingham University Hospitals NHS Trust, Nottingham, UK, 6Hospital Universitario Valle Hebron, Barcelona, Spain, 7Arrow Therapeutics Ltd, London, UK. *edgane@adhb.govt.nz | 2003 |
| DETECTION OF MIXTURES OF HEPATITIS C VIRUS (HCV) TYPES M. Holodniy1*, R.S. Diaz2, R.L. Mathis3, P.M. Feorino3, C. Loveday4, Z. Grossman5, R. Kantor6, Y.W. Tang7, R.M. Lloyd, Jr3 1AIDS Research Center, VA Palo Alto Healthcare System, Palo Alto, CA, USA, 2Retrovirology Laboratory, Federal University of São Paulo, São Paulo, Brazil, 3CSO, Research Think Tank, Inc., Buford, GA, USA, 4ICVC Charitable Trust HQ, Buckinghamshire, UK, 5Clinical Virology Laboratory and National Reference Laboratory, Sheba Medical Center, Ramat Gan, Israel, 6Division of Infectious Diseases, Brown University Medical School, Providence, RI, 7Molecular Infectious Diseases Laboratory, Vanderbilt University Medical Center, Nashville, TN, USA. *mark.holodniy@med.va.gov | 2004 |
| VIROLOGIC RESPONSE RATES FOLLOWING 4 WEEKS OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONICALLY-INFECTED HCV GENOTYPE-1 PATIENTS I. Jacobson1*, P.J. Pockros2, J. Lalezari3, E. Lawitz4, M. Rodriguez-Torres5, E. DeJesus6, F. Haas7, C. Martorell8, R. Pruitt9, V. Purohit10, S. Srinivasan10, S. Jagannatha10, K. Rana10, J. Hammond10 1Weill Cornell Medical College, New York, NY, 2The Scripps Clinic, La Jolla, 3Quest Clinical Research, San Francisco, CA, 4Alamo Medical Research, San Antonio, TX, 5Fundacion de Investigacion de Diego and Ponce School of Medicine, Santurce, PR, 6Orlando Immunology Center, Orlando, FL, 7University of Oklahoma-Schusterman Clinic, Tulsa, OK, 8The Research Institute, Springfield, MA, 9Nashville Medical Research Institute and Maria Nathanson Center of Excellence at Saint Thomas Hospital, Nashville, TN, 10Specialty Care, Pfizer, New London, CT, USA. *imj2001@med.cornell.edu | 2005 |
| GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN SIGNIFICANTLY IMPROVES VIROLOGIC RESPONSE AND ALT NORMALIZATION AT END-OF-TREATMENT AND IMPROVES SVR24 COMPARED TO PEG-IFN/RIBAVIRIN IN GENOTYPE-1 CHRONIC HCV PATIENTS I.M. Jacobson1*, J.G. McHutchison2, T.D. Boyer3, E.R. Schiff4, G.T. Everson5, P.J. Pockros6, R.M. Chasen7, J.M. Vierling8,9, E.J. Lawitz10, M. Kugelmas11,12, N.C. Tsai13, M.L. Shiffman14, R.J. Buynak15, A.M. Sheikh16, B. Armstrong17, T.C. Rodell18, D. Apelian18 1Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY, 2Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, 3Department of Medicine, University of Arizona College of Medicine, Tucson, AZ, 4Center for Liver Diseases, University of Miami School of Medicine, Miami, FL, 5Department of Medicine, University of Colorado Denver, Aurora, CO, 6Scripps Clinic, La Jolla, CA, 7Maryland Digestive Disease Research, Laurel, MD, 8Department of Medicine and Surgery, Baylor College of Medicine, 9St. Luke's Episcopal Hospital, Houston, 10Alamo Medical Research, San Antonio, TX, 11South Denver Gastroenterology, PC, 12Center for Disease of the Liver and Pancreas, Swedish Medical Center, Englewood, CO, 13University of Hawaii, Honolulu, HI, 14Liver Institute of Virginia, Bon Secours Health System, Newport News, VA, 15Northwest Indiana Center for Clinical Research, Valparaiso, IN, 16Gastrointestinal Specialists of Georgia, Marietta, GA, 17QST Consultations, LTD, Allendale, MI, 18GlobeImmune, Inc., Louisville, CO, USA. *imj2001@med.cornell.edu | 2006 |
| 4 WEEK THERAPY WITH THE NON-NUCLEOSIDIC POLYMERASE INHIBITOR BI207127 IN COMBINATION WITH PEGINTERFERON-ALFA2A AND RIBAVIRIN IN TREATMENT NAïVE AND TREATMENT EXPERIENCED CHRONIC HCV GT1 PATIENTS D. Larrey1*, A. Lohse2, V. de Ledinghen3, C. Trepo4, T. Gerlach5, J.-P. Zarski6, A. Tran7, P. Mathurin8, R. Thimme9, K. Arastéh10, C. Trautwein11, A. Cerny12, N. Dikopoulos13, M. Schuchmann14, M.H. Heim15, G. Gerken16, J. Stern17, K. Wu17, N. Abdallah18, B. Girlich19, S. Josepf17, B. Wulf20, F. Berger21, J. Steffgen20, BI207127 Study Group 1Hepato-Gastro-Enterology and transplantation service, Hôpital Saint Eloi, Montpellier, France, 2Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany, 3CHU de Bordeaux Hôpital Haut-Levêque Pessac, Bordeaux, 4Hotel Dieu Hospital, Lyon, France, 5Kantonsspital, St. Gallen, Switzerland, 6CHU de Grenoble Hôpital A Michallon, Grenoble, 7Hôpital Archet, Nice, 8Hôpital Claude Huriez, Lille, France, 9Medizinische Universitätsklinik Freiburg, Freiburg im Breisgau, 10EPIMED GmbH Berlin, Berlin, 11Universitätsklinikum Aachen, Aachen, Germany, 12Clinica Luganese Moncucco, Lugano, Switzerland, 13Universitätsklinik Ulm, Ulm, 14Universitätsmedizin Mainz, Mainz, Germany, 15Universitätsspital Basel, Basel, Switzerland, 16Medizinische Universitätsklinik Essen, Essen, Germany, 17Boehringer Ingelheim, Ridgefield, CT, USA, 18Boehringer Ingelheim, Reims, France, 19Boehringer Ingelheim, Basel, Switzerland, 20Boehringer Ingelheim, Biberach, 21Boehringer Ingelheim, Ingelheim, Germany. *dom-larrey@chu-montpellier.fr | 2007 |
| DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256 E.J. Lawitz1*, T.C. Marbury2, B.D. Vince3, N. Grunenberg4, M. Rodriguez-Torres5, M.P. De Micco6, J.N. Tarro7, M.J. Shelton8, S. West8, J. Zong8, A. Bae8, K. Wong9, H.-M. Mo9, D. Oldach8, W. Delaney9, F. Rousseau8 1Alamo Medical Research, San Antonio, TX, 2Orlando Clinical Research Center, Orlando, FL, 3Vince & Associates Clinical Research, Inc., Overland Park, KS, 4Charles River Clinical Services Northwest, Tacoma, WA, USA, 5Fundacion De Investigacion De Diego, Santurce, Puerto Rico, 6Advanced Clinical Research Institute, Anaheim, CA, 7Columbia Research Group, Portland, OR, 8Gilead Sciences, Inc, Durham, NC, 9Gilead Sciences, Inc, Foster City, CA, USA. *lawitz@alamomedicalresearch.com | 2008 |
| SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAÏVE GENOTYPE-1 CHRONIC HCV PATIENTS E. Lawitz1*, M. Rodriquez-Torres2, V.K. Rustgi3, T. Hassanein4, M.H. Rahimy5, C.A. Crowley5, J.L. Freddo5, A. Muir6, J. McHutchison6 1Alamo Medical Research, San Antonio, TX, 2Fundación de Investigación de Diego, Santurce, PR, 3Metropolitan Research, Fairfax, VA, 4SCTI Research Foundation, Liver Center, San Clemente, 5Anadys Pharmaceuticals, Inc, San Diego, CA, 6Duke Clinical Research Institute, Durham, NC, USA. *lawitz@alamomedicalresearch.com | 2009 |
| Q2WEEK CONTROLLED-RELEASE-INTERFERON-ALPHA2B+RIBAVRIN REDUCES FLU-LIKE SYMPTOMS >50% AND PROVIDES EQUIVALENT EFFICACY IN COMPARISON TO WEEKLY PEGYLATED-INTERFERON-ALPHA2B+RIBAVIRIN IN TREATMENT-NAÏVE-GENOTYPE-1-CHRONIC-HEPATITIS-C: RESULTS FROM EMPOWER, A RANDOMIZED-OPEN-LABEL-12-WEEK-COMPARISON IN 133 PATIENTS W.A. Long1*, D. Takov2, K. Tchernev3, I. Kotzev4, A. Rigney1, Z. Krastev5, S. Stoynov6, R. Balabanska7, E. Lawitz8, Z. Younossi9, R. Ghalib10, E. Zuckerman11, R. Safadi12, R. Tur-Kaspa13, N. Assy14, Y. Lurie15 1Biolex Therapeutics, Pittsboro, NC, USA, 2Military Medical Academy, 3UMHAT “Alexandrovska”, Sofia, 4UMHAT “St. Marina”, Varna, 5UMHAT “St. Ivan Rilski”, 6UMHAT 'Queen Giovanna - ISUL' EAD, 7Tokuda Hospital, Sofia, Bulgaria, 8Alamo Medical Research, San Antonio, TX, 9Inova Health Systems, Falls Church, VA, 10The Liver Institute at Methodist Dallas, Dallas, TX, USA, 11Carmel Medical Center,, Haifa, 12Holy Family Hospital Nazareth, Nazareth, 13Rabin Medical Center, Petah-Tikva, 14Rebekah Ziv Medical Center, Zefat, 15Sourasky Medical Center, Tel Aviv, Israel. *wlong@biolex.com | 2010 |
| IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-A AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION A. Neumann1*, S. Bibert2, B. Haagmans3, A. Soulier4, F. Negro5, M. Lagging6, C. Ferrari7, S. Zeuzem8, J.-M. Pawlotsky4, S. Schalm3, P.-Y. Bochud2, DITTO-HCV group 1Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel, 2Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, 3Erasmus Medical Center, Rotterdam, The Netherlands, 4Hopital Henri Mondor - Universite Paris XII, Creteil, France, 5Hospital University of Geneve, Geneve, Switzerland, 6University of Goeteborg, Goetoborg, Sweden, 7Azienda Ospedaliera di Parma, Parma, Italy, 8University of Frankfurt, Frankfurt, Germany. *neumann@mail.biu.ac.il | 2011 |
| VIROLOGICAL RESPONSE, SAFETY, AND PHARMACOKINETIC PROFILE FOLLOWING SINGLE- AND MULTIPLE-DOSE ADMINISTRATION OF ACH-0141625 PROTEASE INHIBITOR TO HEALTHY VOLUNTEERS AND HCV GENOTYPE-1 PATIENTS V. Detishin1, W. Haazen2, H. Robison3, L. Robarge3, E. Olek3* 1Clinical Hospital of Infectious Diseases and, INNOPHAR MO S.R.L., Chisnau, Moldova, 2SGS Life Science Services, Antwerpen, Belgium, 3Achillion Pharmaceuticals, Inc., New Haven, CT, USA. *eolek@achillion.com | 2012 |
| ANTIVIRAL ACTIVITY, PHARMACOKINETICS AND SAFETY OF IDX184 IN COMBINATION WITH PEGYLATED INTERFERON (PEGIFN) AND RIBAVIRIN (RBV) IN TREATMENT-NAïVE HCV GENOTYPE 1-INFECTED SUBJECTS J. Lalezari1, F. Poordad2*, P. Mehra3, T. Nguyen4, E. Dejesus5, E. Godofsky6, G. Dubuc Patrick7, J. Chen7, K. Pietropaolo7, X.-J. Zhou7, J.Z. Sullivan-Bólyai7, D. Mayers7, IDX-08C-004 Investigator Group 1Quest Clinical Research, San Francisco, 2Cedars-Sinai Medical Center, Los Angeles, 3eStudySite, 4Tuan Trong Nguyen, MD, San Diego, CA, 5Orlando Immunology Center, Orlando, 6University Hepatitis Center at Bach & Godofsky, M.D., P.A., Sarasota, FL, 7Idenix Pharmaceuticals, Inc., Cambridge, MA, USA. *fred.poordad@cshs.org | 2013 |
| IMPROVED INFLAMMATORY ACTIVITY WITH LOW-DOSE PEGINTRON (PEG) MAINTENANCE THERAPY IN PRIOR NONRESPONDERS WITH METAVIR FIBROSIS SCORES (MFS) OF F2/F3: FINAL RESULTS FROM THE EPIC3 PROGRAM T. Poynard1*, J. Bruix2, E. Schiff3, M. Diago4, T. Berg5, R. Moreno-Otero6, L.G. Lyra7, F.J. Carrilho8, N. Boparai9, L. Griffel10, M. Burroughs9, C. Brass9, J.K. Albrecht9 1Service d'Hepato-Gastroenterologie, APHP-UPMC Liver Center, Paris, France, 2Centro de Investigación Biomédica en Red de Enfermedades Hepaticas y Digestivas, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain, 3University of Miami School of Medicine, Miami, FL, USA, 4Hospital General Universitario de Valencia, Valencia, Spain, 5Charité, Campus Virchow Klinikum, Universitätsmedizin Berlin, Berlin, Germany, 6Hospital Universitario de la Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepaticas y Digestivas (Instituto de Salud Carlos III), Madrid, Spain, 7Hospital Sao Rafael, Salvador, 8Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, 9Schering-Plough Corporation, now Merck & Co., Inc., 10Former employee of Schering-Plough Corporation, now Merck & Co., Inc., Whitehouse Station, NJ, USA. *tpoynard@teaser.fr | 2014 |
| GENOME WIDE ANALYSIS OF PATIENTS FROM THE IDEAL STUDY IDENTIFIES A CAUSAL ROLE FOR ITPA GENETIC VARIATION IN RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA A.J. Thompson1*, J. Fellay2, D. Ge2, T. Urban2, K. Shianna2, M. Sulkowski3, A. Muir1, N. Afdhal4, I. Jacobson5, R. Esteban6, F. Poordad7, E. Lawitz8, J. Mc Cone9, M. Shiffman10, G. Galler11, W. Lee12, R. Reindollar13, J. King14, P. Kwo15, R. Ghalib16, B. Freilich17, L. Nyberg18, K. Patel1, H. Tillmann1, S. Noviello19, N. Bopari19, K. Koury19, L. Pedicone19, C. Brass19, J.K. Albrecht19, D. Goldstein2, J.G. Mc Hutchison1 1Duke Clinical Research Institute, 2Institute for Genome Sciences & Policy, Center for Human Genome Variation, Duke University, Durham, NC, 3Johns Hopkins University School of Medicine,, Baltimore, MD, 4Beth Israel Deaconess Medical Centre, Boston, MA, 5Weill Cornell Medical College, New York, NY, USA, 6Hospital General Universitario Valle de Hebron, Barcelona, Spain, 7Cedars-Sinai Medical Center, Los Angeles, CA, 8Alamo Medical Research, San Antonio, TX, 9Mt. Vernon Endoscopy Center, Alexandria, 10Virginia Commonwealth University, Richmond, VA, 11Kelsey Research Foundation, Houston, 12University of Texas Southwestern Medical Center, Dallas, TX, 13Piedmont Healthcare, Statesville, NC, 14Louisiana State University, Shreveport, LA, 15Indiana University School of Medicine, Indianapolis, IN, 16The Liver Institute at Methodist Dallas Medical Center, Dallas, TX, 17Kansas City Gastroenterology and Hepatology, Kansas City, MO, 18Kaiser Permanente, San Diego, CA, 19Schering-Plough Corporation (now Merck & Co., Inc.), Whitehouse Station, NJ, USA. *alexander.thompson@duke.edu | 2015 |
| LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1) J.M. Vierling1*, R. Ralston2, E.J. Lawitz3, J. McCone4, S. Gordon5, D. Pound6, M. Davis7, J. Galati8, I. Jacobson9, L. Rossaro10, F.H. Anderson11, J. King12, W. Cassidy13, M. Bourliere14, R. Esteban-Mur15, N. Ravendhran16, G. Galler17, P. Mendez2, C.A. Brass2, J.K. Albrecht2 1Advanced Liver Therapies/St. Luke's Episcopal Hospital, Houston, TX, 2Merck Research Laboratories, Kenilworth, NJ, 3Alamo Medical Research, San Antonio, TX, 4Mount Vernon Endoscopy Center, Alexandria, VA, 5Henry Ford Hospitals, Detroit, MI, 6Indianapolis Gastroenterology Research Foundation, Indianapolis, IN, 7South Florida Center of Gastroenterology, Wellington, FL, 8Liver Specialists of Texas, Houston, TX, 9Weill Medical College of Cornell University, New York, NY, 10Davis Medical Center, University of California, Sacramento, CA, USA, 11The Liver and Intestinal Research Centre, Vancouver, BC, Canada, 12LSU Medical Center; Louisiana State University, Shreveport, 13Louisiana State University, Baton Rouge, LA, USA, 14Hospital Saint Joseph, Marseille Cedex, France, 15Hospital Vall d'Hebron, Barcelona, Spain, 16Digestive Disease Associates, Baltimore, MD, 17Kelsey Research Foundation, Houston, TX, USA. *vierling@bcm.tmc.edu | 2016 |